➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
McKinsey
Colorcon
Mallinckrodt
Express Scripts

Last Updated: November 28, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,987,231

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,987,231
Title:Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising acetylsalicylic acid, or pharmaceutically acceptable salt thereof, and omeprazole, or pharmaceutically acceptable salt thereof.
Inventor(s): Plachetka; John R. (Chapel Hill, NC)
Assignee: POZEN INC. (Chapel Hill, NC)
Application Number:15/338,825
Patent Claims: 1. A method for delivering a pharmaceutical composition to a patient in need thereof, comprising orally administering to said patient a pharmaceutical composition in unit dose form comprising acetylsalicylic acid, or pharmaceutically acceptable salt thereof, in an amount to provide 325 mg of acetylsalicylic acid, and omeprazole, or pharmaceutically acceptable salt thereof, in an amount to provided 40 mg of omeprazole, wherein said omeprazole, or pharmaceutically acceptable salt thereof, is released from said unit dose form at a pH of from about 0 or greater, and the unit dose form targets: i) a pharmacokinetic (pk) profile for acetylsalicylic acid where: a) the dose has a acetylsalicylic acid mean C.sub.max of about 2.0 to about 3.0 .mu.g/mL and a median time to maximum concentration (T.sub.max) of from about 3.0 to about 3.5 hours, and/or b) the dose has a salicylic acid mean C.sub.max of about 15 to about 16.5 .mu.g/mL and a median time to maximum concentration (T.sub.max) of from about 3.0 to about 3.5 hours, ii) a pharmacokinetic (pk) profile for omeprazole where the dose has a mean area under the plasma concentration-time curve from time zero when the dose is administered to about 12 hours after the dose is administered (AUC.sub.0-12) of about 0.8 to about 2.5 hr/*.mu.g/mL wherein the pharmaceutical composition further targets a mean % time at which intragastric pH remains at about 4.0 or greater for about a 24 hour period after reaching steady state of at least about 50%.

2. The method according to claim 1, wherein the pk profile for acetylsalicylic acid has a mean acetylsalicylic acid C.sub.max of at least 2.36 .mu.g/ml and a mean salicylic acid C.sub.max of at least 15.3 .mu.g/ml.

3. The method according to claim 1, wherein the pk profile for acetylsalicylic acid has a mean acetylsalicylic acid C.sub.max of about 2.91 .mu.g/ml and a mean salicylic acid C.sub.max of at least 16.2 .mu.g/ml.

4. The method according to claim 3, wherein the % coefficient of variation for acetylsalicylic acid is about 54%, and the coefficient of variation for salicylic acid is about 29%.

5. The method according to claim 1, wherein the omeprazole mean area under the plasma concentration-time curve from time zero when the dose is administered to about 12 hours after the dose is administered (AUC.sub.0-12) is about 2.174 hr/*.mu.g/mL.

6. The method according to claim 5, wherein the % coefficient of variation for the omeprazole mean area under the plasma concentration-time curve from time zero when the dose is administered to about 12 hours after the dose is administered (AUC.sub.0-12) is about 88%.

7. The method according to claim 1, wherein the omeprazole mean area under the plasma concentration-time curve from time zero when the dose is administered to about 24 hours after the dose is administered (AUC.sub.0-24) of about 2.187 hr/*.mu.g/mL.

8. The method according to claim 7, wherein the % coefficient of variation for the omeprazole mean area under the plasma concentration-time curve from time zero when the dose is administered to about 24 hours after the dose is administered (AUC.sub.0-24) is about 88%.

9. The method according to claim 1, wherein said unit dose form is administered for a period of at least about 7 days.

10. The method according to claim 1, wherein said unit dose form is administered for a period of at least about 14 days.

11. The method according to claim 1, wherein said unit dose form is a multilayer tablet comprising at least one core and at least a first layer and a second layer, wherein: i) said core comprises acetylsalicylic acid, or pharmaceutically acceptable salt thereof; ii) said first layer is a coating that at least begins to dissolve when the pH of the surrounding medium is about 3.5 or greater; and iii) said second layer comprises omeprazole, wherein said omeprazole is released at a pH of from about 0 or greater.

12. The method according to claim 11, wherein said omeprazole is released at a pH of from about 0 to about 2.

13. The method according to claim 1, wherein said patient in need thereof is being treated for a disease or disorder selected from pain and inflammation.

14. The method according to claim 1, wherein said patient in need thereof is being treated for cardiovascular disease, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, or a combination thereof.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Colorcon
Merck
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.